Dr. Bishr Abdassalam Al-Ujayli, MD

Dr. Al-Ujayli practices at Corewell Health Beaumont Grosse Pointe Hospital in Grosse Pointe, Michigan, part of Corewell Health.

Dr. Al-Ujayli's NPI, 1790797355, was assigned on August 12, 2006. Dr. Al-Ujayli holds Michigan license 4301054466.

Dr. Al-Ujayli's primary practice is Corewell Health Beaumont Grosse Pointe Hospital, at 468 Cadieux Rd, Grosse Pointe, MI 48230 in Wayne County. The practice phone is (313) 473-1000.

Dr. Al-Ujayli's primary practice is Corewell Health Beaumont Grosse Pointe Hospital in Grosse Pointe, Michigan, part of Corewell Health. Dr. Al-Ujayli is also affiliated with Corewell Health William Beaumont University Hospital. The medical group on file is Bishr Ujayli MD PC. Dmand AI also links Dr. Al-Ujayli to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Al-Ujayli practices, 7 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Al-Ujayli's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Al-Ujayli is licensed in Michigan.

CMS data shows 1,508 Medicare services from Dr. Al-Ujayli across 5 procedure codes in 2024, for 502 Medicare patients. Medicare paid $120,071 for them.

CMS counts 502 Medicare patients who saw Dr. Al-Ujayli in 2024. The largest group is 75 to 84, with 168 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Al-Ujayli's median patient age at 65, with 63% women.

In 2024, Dr. Al-Ujayli wrote 527 Medicare Part D claims for 186 patients. 88% of them were for generic drugs. CMS names the drug for 423 of them, across 18 drugs with 11 or more claims each, at $101,171 in total drug cost. In 2023, CMS named 357 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Al-Ujayli for performance year 2024, reported as part of a group. Dr. Al-Ujayli accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 106 general payments to Dr. Al-Ujayli from 21 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 87% of the total. Astellas Pharma US Inc paid the most, $392.